Proteolix Presents Positive Clinical Data for Carfilzomib in Multiple Myeloma at the 2009 ASCO Annu... (enrolled a total of forty-six heavily pr...)

Proteolix Presents Positive Clinical Data for Carfilzomib in Multiple Myeloma at the 2009 ASCO Annual Meeting

Date:6/1/2009

enrolled a total of forty-six heavily pre-treated multiple myeloma patients who had failed all other approved agents. Of 39 evaluable patients who received a dose of 20mg/m(2), 18 percent achieved an overall response and 26 percent achieved a clinical benefit response. An additional 41 percent achieved stable disease. Importantly, responses have also been sustained; patients achieving partial or minor responses stayed on therapy for a median treatment duration of 240 days, or approximately 8 months, and the median duration of response was 7.4 months. Ten percent of patients completed twelve cycles of treatment and an extension study has been initiated for patients who have stayed on drug for one year.

All patients enrolled in the Phase 2 trial have relapsed following treatment with bortezomib and an immunomodulatory agent, such as thalidomide or lenalidomide, and were refractory to their last treatment. Eighty percent of patients received at least four prior treatments. Of 26 patients enrolled who were refractory to treatment with bortezomib, 19 percent achieved a clinical benefit response.

Carfilzomib was generally well tolerated and toxicities were manageable. The most common adverse events reported were fatigue, anemia and thrombocytopenia. Of note to this patient population, treatment with carfilzomib was associated with a low incidence of peripheral neuropathy, a common side effect associated with the approved proteasome inhibitor, bortezomib. Exacerbation of pre-existing peripheral neuropathy was rare and did not result in dose reductions or discontinuation of therapy. Overall, adverse events did not limit treatment duration, even among patients with several co-morbidities.

These data were presented by Dr. Jagannath in an oral presentation titled "Final results of PX-171-003-A0, part 1 of an open-label, single-arm, Phase II study of carfilzomib in patients with relapsed and refractory multiple m
'/>"/>

SOURCE Proteolix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6
Related medicine technology :

1. Proteolix Presents Phase 1b/2 Clinical Data for Carfilzomib in Advanced Solid Tumor Patients at the 2009 ASCO Annual Meeting
2. Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology
3. Proteolix Initiates Phase 1b Clinical Trial of Carfilzomib in a Combination Regimen for Patients With Relapsed Multiple Myeloma
4. Proteolix Initiates Phase 2 Clinical Trial of Carfilzomib in Patients With Relapsed Solid Tumors
5. Proteolix Initiates Multicenter Open-label Study of the Safety and Activity of Carfilzomib in Subjects With Relapsed Solid Tumors
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. Entremed Presents Results of ENMD-2076 Phase 1 Study in Advanced Cancer Patients
8. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
9. TYRX Presents Early Clinical Results from AIGISRX(TM) Antibacterial Envelope Retrospective Registry
10. Paloma Pharmaceuticals Presents at the Association for Research in Vision and Ophthalmology 2009 Meeting
11. MedImmune Presents New Data Demonstrating Increased Risk for Medically Attended RSV in Late-Preterm Infants

Post Your Comments:

(Date:5/24/2013)... , May 24, 2013 An international roster of ... May 18, in Santa Monica, Calif. ... lung-sparing therapies for MPM, a rare form of cancer ... the pleura, the lining of the chest. ... Blood Institute, the 3rd Annual International Symposium on Lung-Sparing ...

(Date:5/24/2013)... , May 24, 2013 China Biologic Products, ... leading fully integrated plasma-based biopharmaceutical company in ... recently learned from a public announcement issued by Shanghai ... company listed on Shenzhen Stock Exchange, that on May ... ("Ms. Chan"), one of the shareholders of the ...

(Date:5/24/2013)... -- In accordance with Rule 17.1 and Rule 2.9 of ... States Exchange Act, Echo Pharma Acquisition Limited ("Royalty Pharma") today ... ELN). Background On 2 May 2013, ... the entire of the issued and to be issued share ... On 20 May 2013, Royalty Pharma announced the ...

Breaking Medicine Technology:International Mesothelioma Experts Present Promising New Research Findings at the 3rd Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma 2 International Mesothelioma Experts Present Promising New Research Findings at the 3rd Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma 3 China Biologic Comments on the Proposed Shanghai RAAS Transaction 2 China Biologic Comments on the Proposed Shanghai RAAS Transaction 3 China Biologic Comments on the Proposed Shanghai RAAS Transaction 4 Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 2 Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 3 Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 4 Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 5 Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 6 Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 7 Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 8 Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 9

[0] International Mesothelioma Experts Present Promising New Research Findings at the 3rd Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma [0] China Biologic Comments on the Proposed Shanghai RAAS Transaction [0] Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements

... YORK, June 15, 2007 /PRNewswire/ -- Telomerase Activation,Sciences, Inc. ... Anti-Aging Trial of TA-65, the first human trial,ever to ... Activator. Statistically significant,results were found in those taking TA-65 ... -- Improvement in immune system function, ...

... Trial Presented at EULAR, BARCELONA, Spain, June ... the European League Against Rheumatism (EULAR),Annual European ... spondylitis (AS) who received REMICADE(R) (infliximab),over two ... addition, REMICADE-treated patients showed sustained,reductions in spinal ...

Geron Corp. Licensee TA Sciences Announces Landmark 7/07/07,Teleconference to Answer Questions About TA-65, Their Telomerase,Activator With Proven Age Management Benefits Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation

(Date:5/25/2013)... 25, 2013 According to a ... Market, 2013–2018", published by MarketsandMarkets is expected to ... of 5.54% which analyzes and studies the major ... Europe, Asia, and Rest of the World. , ... Tables , 87 Figures , ...

(Date:5/25/2013)... According to world-renowned scholars, Queen Cleopatra ... women that ever lived. Cleopatra’s legendary beauty moved nations ... most powerful men in her time. Cleopatra was also ... her skin glowing and fresh, from her legendary milk ... oil and cyprus grass. , Cleopatra was said to ...

(Date:5/25/2013)... May 25, 2013 IBISWorld estimates that revenue ... an average annual rate of 28.7% to $1.0 billion in ... 2013. From 2002 and 2008, no new cell therapy products ... relatively modest growth during that period. In the years since, ... new products. This factor contributed to the industry's fast growth ...

(Date:5/25/2013)... DF (PRWEB) May 25, 2013 Ayurveda ... sanscrit: "knowledge or wisdom of life". While a medical science, ... the transformation of consciousness. Its fundamental philosophy is that disease ... our environment. In order to re-establish optimal health, one must ... adopt a life style which brings us back into perfect ...

(Date:5/25/2013)... 2013 The current residents of Back2Basics - ... the B2B staff all came together Saturday, May 18th to ... of Indian Cuisine, the residents got up to thank Roy ... on their road to recovery, and giving them a second ... center in 2010 after realizing the need for a long-term ...

Breaking Medicine News(10 mins):Health News:Homeland Security Market to Reach $544.02 Billion by 2018 at a CARC of 5.54% - New Report by MarketsandMarkets 2 Health News:Homeland Security Market to Reach $544.02 Billion by 2018 at a CARC of 5.54% - New Report by MarketsandMarkets 3 Health News:Homeland Security Market to Reach $544.02 Billion by 2018 at a CARC of 5.54% - New Report by MarketsandMarkets 4 Health News:The Cleopatra Lift - A New Non Surgical Option to Aging Offered by Vancouver Physician 2 Health News:The Cleopatra Lift - A New Non Surgical Option to Aging Offered by Vancouver Physician 3 Health News:Slow Healing: Cell Therapy in the US Industry Market Research Report Now Available from IBISWorld 2 Health News:Slow Healing: Cell Therapy in the US Industry Market Research Report Now Available from IBISWorld 3 Health News:Fundamentos de Ayurveda in Mexico (Ayurvedic Principles) Offered by Escuela de Ayurveda de California 2 Health News:Back2Basics Drug and Alcohol Rehabilitation Center Celebrates Their 3rd Anniversary 2

[0] Homeland Security Market to Reach $544.02 Billion by 2018 at a CARC of 5.54% - New Report by MarketsandMarkets [0] The Cleopatra Lift - A New Non Surgical Option to Aging Offered by Vancouver Physician [0] Slow Healing: Cell Therapy in the US Industry Market Research Report Now Available from IBISWorld [0] Fundamentos de Ayurveda in Mexico (Ayurvedic Principles) Offered by Escuela de Ayurveda de California [0] Back2Basics Drug and Alcohol Rehabilitation Center Celebrates Their 3rd Anniversary

... Holdings, Inc. (NYSE Alternext US: KUN) ("China Shenghuo" ... previous,announcements, it has filed with the United States ... Report on Form 10-KSB/A for the year,ended December ... 10-Q/A for the,first quarter ended March 31, 2008 ...

... 20 Again next year, the American Pain,Society (APS), ... programs in its acclaimed Clinical Centers of Excellence in ... until Dec. 14,2008. , ... Awards Program,honors forward-thinking teams of healthcare professionals who are ...

... volunteers from State,Farm Bayou Classic(R), organizers from KaBOOM! and residents ... 28 to build a new, safe,playground at the Abramson Science ... is based on drawings provided by,children who attended a Design ... The new playground will provide more than 400 children ...

... Contreras, 61, and Ramon Pichardo, 58, were sentenced today to ... the Medicare program in connection with a $6.8 million HIV ... the Criminal Division and U.S. Attorney R. Alexander Acosta of ... , Judge Federico A. Moreno of ...

... differ by almost $37,000 per patient, study finds , , ... treating colorectal cancer can vary by tens of thousands ... researchers compared the eight most commonly prescribed therapeutic regimens ... ambulatory care centers across the United States. , ...

... in these young adults points to danger, study finds ... the arteries of children of smokers can be detected ... Dutch study finds. , "Smoking in families is harmful ... in many other studies," said research leader Dr. Cuno ...

China Shenghuo Announces Restated Results For Full Year 2007 & First Quarter 2008, Reports Results For Second & Third Quarter 2008 American Pain Society Accepting Applications for Clinical Centers of Excellence in Pain Management Awards State Farm Bayou Classic and KaBOOM! Team Up to Build New Playground in Just One Day Miami Physicians Sentenced to Prison for Their Roles in a $6.8 Million Medicare Fraud Scheme Colorectal Cancer Treatment Costs Vary Widely Parent Smoking During Pregnancy Raises Kids' Heart Risks

... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...

... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...

... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...

... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...

Medicine Products:

NPM-ALK, t(2;5) Translocation, Quantitative by RT-PCR, Fluid Nortriptyline by HPLC Norwalk Virus Norpace